



Population data in thousands ¹								
	2018	2017	2016	2015	2014	2000	1990	1980
Total population	926'911	923'248	919'366	915'412	911'433	866'251	845'992	796'994
Live births	11'139	11'243	11'327	11'388	11'425	10'245	12'549	13'363
Surviving infants	11'058	11'157	11'236	11'293	11'324	10'061	12'203	12'871
Pop. less than 5 years	56'743	56'918	57'050	57'161	57'004	51'135	64'186	63'850
Pop. less than 15 years	167'678	166'347	164'902	163'485	161'954	172'232	192'087	192'390
Female 15-49 years	429'832	431'366	433'024	434'851	437'041	442'218	418'958	396'607
Number of reported cases								
Diphtheria	73	35	47	59	35	1'585	3'202	618
Japanese encephalitis	0	3	0	1	1	-	-	-
Measles	82'523	24'356	4'363	25'965	14'176	37'421	234'827	851'849
Mumps	19'845	26'803	20'874	10'027	10'807	243'344	-	-
Pertussis	55'767	63'037	69'490	43'615	43'858	53'675	129'735	90'546
Polio	0	0	0	2	0	0	370	549
Rubella	798	842	1'471	655	653	621'039	-	-
Rubella (CRS)	14	17	6	14	28	47	-	-
Tetanus (neonatal)	0	0	0	1	1	27	69	26
Tetanus (total)	81	134	137	122	68	412	879	1'715
Yellow fever	4	0	1	0	0	0	-	-
Percentage of target population vaccinated, by antigen								
<i>based on WHO-UNICEF estimates</i>								
<i>TT2plus is based on reported coverage</i>								
BCG	93	92	92	90	90	93	84	20
DTP1	97	97	96	96	96	96	89	70
DTP3	94	94	92	93	93	93	80	63
HepB_BD	39	39	40	41	41	13	-	-
HepB3	84	83	82	82	81	42	0	-
Hib3	76	76	76	76	77	38	0	-
IPV1	85	71	73	69	-	-	-	-
MCV1	95	95	93	94	94	91	83	55
MCV2	91	90	88	89	89	48	-	-
PCV3	78	73	62	48	46	-	-	-
Pol3	93	93	94	94	94	94	84	72
RCV1	95	95	93	94	94	60	29	4
rotac	25	25	24	23	12	-	-	-
TT2plus	83	83	83	83	84	38	17	0

Most countries have standard recommendations regarding which vaccines should be offered and at what ages they should be given. In general, vaccines are recommend for the youngest age group at risk for developing the disease whose members are known to respond to the immunization without adverse effects.

Estimates for a dose of inactivated polio vaccine (IPV) begin in 2015 following the Global Polio Eradication Initiative's Polio Eradication and Endgame Strategic Plan: 2013-2018 which recommended at least one full dose or two fractional doses of IPV into routine immunization schedules as a strategy to mitigate the potential consequences should any re-emergence of type 2 poliovirus occur following the planned withdrawal of Sabin type 2 strains from oral polio vaccine (OPV). IPV global and regional coverage calculation is for 144 bOPV using countries.

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.

1) "United Nations, Population Division. The World Population Prospects - the 2019 revision". New York, 2019.